WebDec 14, 2024 · BOSTON and LONDON, Dec. 14, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA), together with subsidiary Palladio … WebAug 17, 2024 · The Centessa Subsidiaries are ApcinteX, Capella BioScience, Janpix, LockBody, Morphogen-IX, Orexia Therapeutics, Palladio Biosciences, PearlRiver Bio, Pega-One and Z Factor. The current Centessa Pharmaceuticals portfolio consists of four clinical-stage programs, including two that are in late-stage clinical development, and …
Annemieke Vink - Therapeutic Strategy Director …
WebSince March 2024 I started as Director Clinical Operations at Palladio Biosciences, a Centessa Company. Due to termination of the trial and … WebPrior to that, she was the Chief Financial Officer of Palladio Biosciences Inc., before its acquisition by Centessa. Previously, Ms. Thorell served as Chief Financial Officer, Chief Operating Officer and Executive Director of Realm Therapeutics until the company was acquired by ESSA in 2024. ederhof angus
Centessa Pharmaceuticals Reports Fourth Quarter and 2024 …
WebFeb 16, 2024 · Centessa Pharmaceuticals (“Centessa”) launched today as a novel asset-centric pharmaceutical company designed and built to advance a portfolio of highly validated programs. Centessa’s asset-centric R&D model applied at scale has assembled best-in-class or first-in-class assets, each of which is led by specialized teams committed to ... WebFeb 17, 2024 · Palladio Biosciences is developing lixivaptan, an oral non-peptide, new chemical agent that works by selectively suppressing the activity of the hormone vasopressin at the V2 receptor, as a treatment for autosomal dominant polycystic kidney disease with the goal of slowing the progression of kidney function decline and avoiding … WebFeb 16, 2024 · Palladio Biosciences is developing lixivaptan, an oral non-peptide, new chemical agent that works by selectively suppressing the activity of the hormone vasopressin at the V2 receptor, as a... coney island new york at night